Conferences - Results from #7100

ASCO GU 2019: Results from KEYNOTE-427 Cohort Bb - First-line Pembrolizumab Monotherapy for Advanced Non-Clear Cell RCC February 20, 2019

ASCO GU 2019: Final Analysis from the NIVOREN GETUG AFU 26 Study February 20, 2019

ASCO GU 2019: PIVOT-02 Study of NKTR-214 with Nivolumab in Metastatic Urothelial Carcinoma February 20, 2019

ASCO GU 2019: Health-Related Quality of Life Reporting in Phase III Randomized Controlled Trials of Metastatic Prostate Adenocarcinoma and Urothelial Carcinoma February 20, 2019

ASCO GU 2019: Study of Durvalumab Given with Chemotherapy, Durvalumab in Combination with Tremelimumab Given with Chemotherapy, or Chemotherapy in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer February 20, 2019

ASCO GU 2019: Gemcitabine-Carboplatin versus Gemcitabine-Oxaliplatin In Cisplatin Un-Fit Advanced Urothelial Carcinoma: Randomized Phase II Study-COACH Study February 19, 2019

ASCO GU 2019: RENAVIV: Pazopanib with or without Abexinostat in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma February 19, 2019

ASCO GU 2019: PROSPER: Comparing Perioperative Nivolumab versus Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy February 19, 2019

ASCO GU 2019: Gemcitabine Plus Axitinib in Patients with Sarcomatoid Type Renal Carcinoma February 19, 2019

ASCO GU 2019: Novel Predictive Models of Early Death Less than One Year in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitors February 19, 2019

ASCO GU 2019: Results of a Phase II Study to Evaluate the Safety and Efficacy of RX-0201 in Combination with Everolimus in Subjects with mRCC February 19, 2019

ASCO GU 2019: A Phase II study of Cabozantinib as First-line Treatment in Metastatic Collecting Duct Carcinoma: The BONSAI Trial February 19, 2019

ASCO GU 2019: CheckMate 9UT - Nivolumab or Nivo Plus BMS-986205 with or without Intravesical Bacillus Calmette-Guerin in BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer February 19, 2019

ASCO GU 2019: POTOMAC Study - Durvalumab and BCG versus BCG Alone in High-risk, BCG-Naïve Non Muscle-Invasive Bladder Cancer February 19, 2019

ASCO GU 2019: Renal Function Preservation in Kidney Cancer: Current Techniques and Biomarkers February 19, 2019

ASCO GU 2019: Phase II Study of Ribociclib in Men with Unresectable, Incurable Teratoma with Recent Progression February 19, 2019

ASCO GU 2019: Malignant Pheochromocytoma: Comprehensive Genomic Profiling Study February 19, 2019

ASCO GU 2019: Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer February 19, 2019

ASCO GU 2019: Prevention of Symptomatic Skeletal Events with Denosumab: REDUSE Trial February 19, 2019

ASCO GU 2019: Accelerated versus Standard BEP Chemotherapy for Adult and Pediatric Male and Female Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors February 19, 2019

Page 356 of 619